MX2016012751A - Profarmacos de succionato para uso en el tratamiento de acidosis lactica o efectos secundarios inducidos por farmaco debido al deterioro relacionado con el complejo i de fosforilacion oxidativa mitocondrial. - Google Patents

Profarmacos de succionato para uso en el tratamiento de acidosis lactica o efectos secundarios inducidos por farmaco debido al deterioro relacionado con el complejo i de fosforilacion oxidativa mitocondrial.

Info

Publication number
MX2016012751A
MX2016012751A MX2016012751A MX2016012751A MX2016012751A MX 2016012751 A MX2016012751 A MX 2016012751A MX 2016012751 A MX2016012751 A MX 2016012751A MX 2016012751 A MX2016012751 A MX 2016012751A MX 2016012751 A MX2016012751 A MX 2016012751A
Authority
MX
Mexico
Prior art keywords
treatment
drug
complex
effects due
lactic acidosis
Prior art date
Application number
MX2016012751A
Other languages
English (en)
Inventor
Joakim Hansson Magnus
Henrik Johannes Ehinger Karl
Moss Steven
Elmér Eskil
PIEL Sarah
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MX2016012751A publication Critical patent/MX2016012751A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un profármaco de succinato para uso en el tratamiento o prevención de acidosis láctica.
MX2016012751A 2014-04-08 2015-04-08 Profarmacos de succionato para uso en el tratamiento de acidosis lactica o efectos secundarios inducidos por farmaco debido al deterioro relacionado con el complejo i de fosforilacion oxidativa mitocondrial. MX2016012751A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA201470187 2014-04-08
DKPA201470190 2014-04-08
DKPA201470185 2014-04-08
PCT/EP2015/057615 WO2015155238A1 (en) 2014-04-08 2015-04-08 Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation

Publications (1)

Publication Number Publication Date
MX2016012751A true MX2016012751A (es) 2016-12-12

Family

ID=52988028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012751A MX2016012751A (es) 2014-04-08 2015-04-08 Profarmacos de succionato para uso en el tratamiento de acidosis lactica o efectos secundarios inducidos por farmaco debido al deterioro relacionado con el complejo i de fosforilacion oxidativa mitocondrial.

Country Status (14)

Country Link
US (1) US10307389B2 (es)
EP (1) EP3129058A1 (es)
JP (1) JP2017510603A (es)
KR (1) KR20160135365A (es)
CN (1) CN106255509A (es)
AU (1) AU2015243353A1 (es)
CA (1) CA2944575A1 (es)
EA (1) EA201692020A1 (es)
IL (1) IL247958A0 (es)
MA (1) MA39857A (es)
MX (1) MX2016012751A (es)
SG (1) SG11201607908QA (es)
WO (1) WO2015155238A1 (es)
ZA (1) ZA201606611B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201810411T4 (tr) 2014-04-08 2018-08-27 Neurovive Pharmaceutical Ab Özgün hücre geçirgen süksinat bileşikleri.
WO2017060418A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
WO2017060420A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected fumaric acid-based metabolites for the treatment of autoimmune diseases
WO2017060422A1 (en) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of mitochondrial disorders
CN113993842B (zh) * 2019-06-19 2024-07-16 爱博利瓦有限公司 琥珀酸酯前药、包含琥珀酸酯前药的组合物及其用途
CN112479913A (zh) * 2020-11-19 2021-03-12 安徽修一制药有限公司 一种n,n-二乙基氯代乙酰胺的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651758B2 (en) * 1992-02-07 1994-07-28 Tsumura & Co. Side-effect alleviant
GB9612331D0 (en) * 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) * 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
CA2536111A1 (en) * 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases
KR100791844B1 (ko) 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
KR101069502B1 (ko) * 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
US8252840B2 (en) * 2007-03-26 2012-08-28 Salutria Pharmaceuticals Llc Methods of derivatives of probucol for the treatment of type II diabetes
IT1406068B1 (it) * 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
JP2014024772A (ja) 2012-07-25 2014-02-06 Univ Of Tokyo ミトコンドリアのａｔｐ産生能昂進剤
WO2014053857A1 (en) * 2012-10-05 2014-04-10 Mitopharm Ltd Protected succinates for enhancing mitochondrial atp-production
TR201810411T4 (tr) 2014-04-08 2018-08-27 Neurovive Pharmaceutical Ab Özgün hücre geçirgen süksinat bileşikleri.
CA2944560A1 (en) 2014-04-08 2015-10-15 Eskil Elmer Prodrugs of succinic acid for increasing atp production

Also Published As

Publication number Publication date
CA2944575A1 (en) 2015-10-15
MA39857A (fr) 2017-02-15
SG11201607908QA (en) 2016-10-28
KR20160135365A (ko) 2016-11-25
US20170100359A1 (en) 2017-04-13
EP3129058A1 (en) 2017-02-15
AU2015243353A1 (en) 2016-10-13
US10307389B2 (en) 2019-06-04
WO2015155238A1 (en) 2015-10-15
EA201692020A1 (ru) 2017-02-28
CN106255509A (zh) 2016-12-21
JP2017510603A (ja) 2017-04-13
ZA201606611B (en) 2018-05-30
IL247958A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
HK1247922A1 (zh) 用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
EP3458053A4 (en) USE OF RILUZOLE, RILUZOLE PRODRUGS OR RILUZOLE ANALOGS WITH IMMUNOTHERAPIES TO TREAT CANCERS
IL272724B (en) Gemcitabine drug inhibitors
MX2016012751A (es) Profarmacos de succionato para uso en el tratamiento de acidosis lactica o efectos secundarios inducidos por farmaco debido al deterioro relacionado con el complejo i de fosforilacion oxidativa mitocondrial.
IL266012A (en) Combination therapy for c3 inhibition
HK1244023A1 (zh) 水溶性超分子複合物
MX2017000363A (es) Inhibicion de la via de notch.
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
IL247267A0 (en) Methods for the treatment of vascular invasive cancers
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
EP3226869A4 (en) Kinase inhibitor prodrug for the treatment of cancer
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
GB201612872D0 (en) Prodrug compounds
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
IL252493A0 (en) Compounds for use in the prevention or treatment of cancer
MX2016014255A (es) Producto ceramico refractario.
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.
BR112016019395A2 (pt) composição
PH12017501063A1 (en) Compounds for the treatment of cancer
GB2546703A (en) Compounds
TR201401768A2 (tr) Miyasteninin tedavisine yönelik bir kompozisyon.
TR201401730A2 (tr) Artroz'un semptomatik tedavisine yönelik bir kompozisyon.
AU2014126V (en) WA 2 Malus domestica